Tivozanib Withdrawn Phase 2 Trials for Renal Cell Adenocarcinoma Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01834183Tivozanib + Gemcitabine in Metastatic RCC